Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richmond Owusu

Urology San Diego, CA Medical Doctor

NPI 1225458599 CMS profile 1385981

200 W Arbor Dr, Mc 8897, San Diego, CA 92103

Open in the dashboard

General payments

$3,989

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richmond Owusu of San Diego, CA is reported in the CMS Open Payments database as having received $3,989 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $490 10
2024 General $2,935 19
2023 General $76 4
2022 General $176 9
2020 General $32 2
2019 General $280 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richmond Owusu
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Richmond Owusu were reported at $490. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Richmond Owusu Urology median Middle half National median
2019 $280 $480 $147–$1,201 $163
2020 $32 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $176 $476 $143–$1,263 $149
2023 $76 $560 $168–$1,461 $160
2024 $2,935 $563 $170–$1,464 $164
2025 $490 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $1,783 13 payments
  2. PROCEPT BioRobotics Corporation $1,390 8 payments
  3. Olympus America Inc. $143 3 payments
  4. Boston Scientific Corporation $128 3 payments
  5. NeoTract Inc. $90 1 payment
  6. Janssen Biotech, Inc. $64 3 payments
  7. Astellas Pharma US Inc $50 3 payments
  8. Laborie Medical Technologies Corp. $47 3 payments
  9. Cook Medical LLC $39 1 payment
  10. Richard Wolf Medical Instruments Corp. $29 1 payment
  11. Other $226 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,173 39 payments
  2. Travel and Lodging $1,801 10 payments
  3. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,783 13 payments
  2. AQUABEAM SYSTEM $1,013 4 payments
  3. AQUABEAM ROBOTIC SYSTEM $377 4 payments
  4. iTIND System $117 1 payment
  5. GENERAL KIDNEY STONE DISEASE $111 2 payments
  6. UROLIFT $110 2 payments
  7. MYRBETRIQ $50 3 payments
  8. ERLEADA $41 2 payments
  9. Cook Medical Stents $39 1 payment
  10. GEMTESA $33 2 payments
  11. Other $291 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

628

Median for Urology: 1,053

Drug cost

$42,016

Median for Urology: $101,464

Branded share of claims

18.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 27 $35,052
Tamsulosin Hcl Generic 266 $4,145
Finasteride Generic 88 $1,028
Oxybutynin Chloride Er Oxybutynin Chloride Brand 32 $452
Ciprofloxacin Hcl Generic 39 $310
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 11 $299
Oxybutynin Chloride Generic 32 $216
Ketorolac Tromethamine Generic 19 $161
Sildenafil Citrate Generic 21 $125
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 31 $112

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$92,224

Medicare's payments for the services billed

Medicare patients

452

Average age 74

Services billed

973

125 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 48%
Chronic kidney disease 43%
Ischemic heart disease 39%
Cancer 32%
Heart failure 28%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record